Last updated: February 1, 2026
Executive Summary
KRAZATI (adagrasib) is an oral kinase inhibitor developed by Mirati Therapeutics for the treatment of KRAS G12C-mutated solid tumors, notably non-small cell lung cancer (NSCLC). As of early 2023, KRAZATI has received FDA approval for specific indications, reflecting significant progress in targeting historically "undruggable" oncogenic mutations. This report provides an in-depth review of ongoing and completed clinical trials, analyzes current market dynamics, and offers projections based on regulatory milestones, competitive landscape, and clinical data.
Clinical Trials Overview for KRAZATI (adagrasib)
Completed and Ongoing Trials
| Trial ID |
Phase |
Indication |
Status |
Outcomes |
Key Objectives |
| KRYSTAL-1 (NCT04685101) |
Phase 1/2 |
KRAS G12C-mutated NSCLC and other solid tumors |
Ongoing |
ORR 43% (NSCLC); manageable safety profile |
Evaluate efficacy, safety, dosing |
| KRYSTAL-2 (NCT05227724) |
Phase 2 |
NSCLC (first-line treatment) |
Recruiting |
Primary: ORR; Secondary: PFS, OS |
Establish efficacy in first-line setting |
| KRYSTAL-7 (NCT05528277) |
Phase 3 |
Frontline metastatic NSCLC |
Pending |
Efficacy vs standard care |
Confirm superiority or non-inferiority |
| KRYSTAL-X (NCT04793958) |
Phase 1 |
Brain metastases from KRAS G12C tumors |
Ongoing |
Safety, preliminary efficacy |
Assess CNS activity |
Key Clinical Data as of 2023
- Efficacy in NSCLC: The Phase 1/2 KRYSTAL-1 trial reported an objective response rate (ORR) of 43% and a disease control rate (DCR) of 80% among heavily pretreated NSCLC patients with KRAS G12C mutations.
- Progression-Free Survival (PFS): Median PFS was approximately 6.5 months.
- Safety Profile: Generally well-tolerated, with most adverse events (AEs) being grade 1 or 2, including nausea, diarrhea, and fatigue.
- CNS Penetration: Early data suggest activity against brain metastases, an important consideration for NSCLC.
Regulatory Milestones
- FDA Approval (April 2022): KRAZATI received accelerated approval for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC previously treated with at least one prior systemic therapy.
- Ongoing submissions: Mirati Therapeutics continues to compile data for full approval and in additional tumor types.
Market Analysis for KRAZATI
Market Size and Demand Drivers
| Market Segment |
Estimated Market Size (2023) |
Key Drivers |
Growth Rate |
| KRAS G12C NSCLC |
$2.4 billion (globally) [1] |
Increasing prevalence of KRAS mutations; unmet need in resistant patients |
7% CAGR (2023–2028) |
| Other Solid Tumors |
$650 million |
KRAS mutations in colorectal, pancreatic cancers |
8% CAGR |
Source: Global Data, Inc., 2023.
Competitive Landscape
| Competitors |
Drugs |
Indications |
Market Share (2023) |
Status |
| Amgen |
Lumakras (sotorasib) |
KRAS G12C NSCLC |
60% |
Approved since May 2021 |
| Mirati |
KRAZATI (adagrasib) |
KRAS G12C NSCLC |
Estimated 30% |
Approved in 2022 |
| Roche |
لق(bemimetinib) |
MEK inhibitors (indirect competitors) |
N/A |
In development |
Key Points:
- Sotorasib (Lumakras): Dominant market leader, with over 20,000 prescriptions globally (as of 2023).
- Adagrasib's Differentiators: Longer half-life, potential CNS activity, and ongoing trial data may expand its use.
Pricing and Revenue Estimates
| Variable |
Assumption |
Estimated Price per Patient |
Revenue Potential (2023) |
| Price per treatment cycle |
$12,000 |
-- |
-- |
| Average cycles per patient |
6 |
-- |
-- |
| Patient population |
10,000 eligible NSCLC patients |
|
|
| Market penetration |
25% |
|
$180 million |
Note: Prices vary; regulatory and reimbursement policies influence actual revenue.
Policy and Payer Landscape
- FDA approval facilitates market access in the U.S.
- Extended value-based agreements are anticipated due to improved efficacy profiles.
- Pricing negotiations remain critical, especially in Europe and Asia.
Market Projection and Future Outlook
Projection Models (2023–2030)
| Year |
NSCLC KRAS G12C Market (USD millions) |
Additional Indications |
Total Market Growth (%) |
| 2023 |
$180 |
Colorectal and pancreatic (initial) |
7% |
| 2024 |
$240 |
Expanded first-line NSCLC |
12% |
| 2025 |
$350 |
Broader metastatic solid tumors |
15% |
| 2026 |
$500 |
Combination regimens |
20% |
| 2027 |
$700 |
New indications, expanded access |
18% |
| 2028 |
$900 |
Global adoption |
17% |
| 2029 |
$1.2 billion |
Age-specific adjuvant settings |
15% |
| 2030 |
$1.5 billion |
U.S., Europe, Asia markets |
15% |
Assumptions: Continued clinical success, regulatory approval expansion, and increased awareness.
Key Factors Influencing Market Projection
- Clinical success in first-line and adjuvant settings could significantly boost market share.
- Emerging competitors or resistance mechanisms may limit growth.
- Pricing policies and reimbursement frameworks will impact revenue realization.
- Combination therapies with other targeted agents or immunotherapies remain a strategic avenue.
Deep-Dive: Comparative Analysis of KRAZATI and Sotorasib
| Attributes |
KRAZATI (adagrasib) |
Sotorasib (Lumakras) |
| Half-life |
Longer (about 23 hours) |
5 hours |
| CNS Activity |
Preliminary evidence |
Limited data |
| Dosing Frequency |
Once daily |
Once daily |
| Clinical Data |
ORR 43%, median PFS 6.5 months |
ORR ~37%, PFS 6.3 months |
| Regulatory Status |
Approved (2022) |
Approved (2021) |
Implication: Adagrasib's improved pharmacokinetics and activity profile may offer competitive advantages, especially in CNS metastases.
FAQs
-
What are the main indications for KRAZATI?
Currently approved for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have been previously treated.
-
What ongoing trials could expand KRAZATI’s approval?
KRYSTAL-2 (first-line NSCLC), KRYSTAL-7 (phase 3, frontline), and studies exploring activity in colorectal and pancreatic cancers.
-
How does KRAZATI compare to competitors like sotorasib?
It exhibits longer half-life, potentially better CNS penetration, and ongoing data suggest a favorable safety and efficacy profile.
-
What are the primary challenges for KRAZATI’s market growth?
Competition from established therapies, cost and reimbursement hurdles, and resistance mechanisms limiting long-term efficacy.
-
Are combination therapies being considered with KRAZATI?
Yes, clinical trials are exploring combinations with immunotherapy and other targeted agents to improve outcomes.
Key Takeaways
- Regulatory Patent Status: KRAZATI has secured FDA approval via accelerated pathways, with full approval processes ongoing, providing a foundation for future market expansion.
- Clinical Promise: Demonstrates significant activity in heavily pretreated KRAS G12C-mutated NSCLC, with manageable safety, positioning it as a key therapy in this niche.
- Market Dynamics: Sotorasib remains dominant, but KRAZATI’s differentiated pharmacokinetics and ongoing trials could increase its market share.
- Future Growth: Expansion into first-line settings, other tumor types, and combination regimens could double or triple its market size by 2030.
- Strategic Considerations: Monitoring regulatory milestones, clinical trial outcomes, and competitive responses is vital for stakeholders.
References
[1] Global Data, Inc. (2023). Market Forecast for KRAS G12C Inhibitors.
[2] US FDA. (2022). KRAZATI (adagrasib) approval announcement.
[3] Mirati Therapeutics. (2023). Clinical Trial Pipeline Updates.
[4] Pharmaceutical Market Reports. (2023). Oncology Targeted Therapies.
[5] Lu, M., et al. (2022). Pharmacokinetics and efficacy of adagrasib: a phase 1 study. Journal of Thoracic Oncology.
